On May 29, 3SBio rose 5.1% in regular trading, trading at HK$18.1/share, with trading volume of HK$252 million.

On the news front, the ASCO Annual Meeting officially opened today, with 3SBio's core pipeline PD-1/VEGF bispecific antibody SSGJ-707 having two clinical studies selected for presentation, including one receiving a rapid oral report. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In another Phase II study combining chemotherapy as first-line treatment for endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively.

The broader Biotechnology sector rallied in tandem, with Innovent Bio up 10.35%, Akeso up 7.16%, Remegen up 3.17%, PegBio up 1.93%, and BeiGene up 1.48%, reflecting strong sector-wide momentum that further boosted market sentiment around innovative drug names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)